CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

Reviving an ancient human gene that prevents gout and fatty liver disease, scientists at Georgia State University have marked ...

New York, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 ...

Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GenScript ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

Only 10 years ago, Nobel prize-winning work introduced CRISPR, or clustered regularly interspaced short palindromic repeats, as a new and powerful genome editing tool. Since then, many exciting ...

Ottawa, Sept. 01, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the global CRISPR-based gene editing market size was estimated at USD 3.06 billion in 2024. It is predicted to surpass ...

- Related patent application awards by European and Australian Patent Offices already received; similar patents pending elsewhere MilliporeSigma today announced that the Canadian Patent Office has ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...